Form 4: Teva Pharmaceutical Industries: Acting Chief Legal Officer Dov Bergwerk Reports Share Transactions
SEC Form 4 Filing
Dov Bergwerk, Acting Chief Legal Officer of Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent ownership of ordinary shares.
Summary
- On February 28, 2024, Dov Bergwerk, Acting Chief Legal Officer of Teva Pharmaceutical Industries, had 6,653 restricted share units vest.
- These units converted into 6,653 ordinary shares.
- Following the transaction, Bergwerk directly owns 96,983 ordinary shares.
Sentiment
Score: 5
Explanation: This is a neutral report of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine vesting of previously granted compensation.
Key Dates
| Date | Description |
|---|---|
| 02/28/2020 | Restricted share units were granted. |
| 02/28/2024 | Vesting of 6,653 restricted share units. |
| 03/01/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.